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hMENA11a contributes to HER3-mediated resistance to PI3K
inhibitors in HER2-overexpressing breast cancer cells
P Trono1, F Di Modugno1, R Circo2, S Spada1,3, A Di Benedetto4, R Melchionna1, B Palermo1,3, S Matteoni5, S Soddu5, M Mottolese4,
R De Maria6 and P Nisticò1
Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast
cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2
overexpression and an activated status of AKT and MAPK. The concomitant overexpression of hMENA and HER2 in breast cancer
patients is indicative of a worse prognosis. hMENA is expressed along with alternatively expressed isoforms, hMENA11a and
hMENAΔv6 with opposite functions. A novel role for the epithelial-associated hMENA11a isoform in sustaining HER3 activation and
pro-survival pathways in HER2-overexpressing breast cancer cells has been identified by reverse phase protein array and validated
in vivo in a series of breast cancer tissues. As HER3 activation is crucial in mechanisms of cell resistance to PI3K inhibitors, we
explored whether hMENA11a is involved in these resistance mechanisms. The specific hMENA11a depletion switched off the HER3-
related pathway activated by PI3K inhibitors and impaired the nuclear accumulation of HER3 transcription factor FOXO3a induced
by PI3K inhibitors, whereas PI3K inhibitors activated hMENA11a phosphorylation and affected its localization. At the functional level,
we found that hMENA11a sustains cell proliferation and survival in response to PI3K inhibitor treatment, whereas hMENA11a
silencing increases molecules involved in cancer cell apoptosis. As shown in three-dimensional cultures, hMENA11a contributes to
resistance to PI3K inhibition because its depletion drastically reduced cell viability upon treatment with PI3K inhibitor BEZ235.
Altogether, these results indicate that hMENA11a in HER2-overexpressing breast cancer cells sustains HER3/AKT axis activation and
contributes to HER3-mediated resistance mechanisms to PI3K inhibitors. Thus, hMENA11a expression can be proposed as a marker
of HER3 activation and resistance to PI3K inhibition therapies, to select patients who may benefit from these combined targeted
treatments. hMENA11a activity could represent a new target for antiproliferative therapies in breast cancer.
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INTRODUCTION
Members of the ErbB family have a crucial role in breast cancer
(BC) formation and progression. Identification of the mechanisms
involved in their complex signaling network has led to the
development of ErbB-specific inhibitors1 that have improved the
outcome of patients with HER2-positive tumors; however, a
number of patients develop resistance to these drugs. One of
the proposed resistance mechanisms involves reactivation of PI3K
signaling via alternative receptor tyrosine kinase amplified path-
ways and/or mutations in the PI3K pathway.2 Several antagonists
of the PI3K pathway have been entered in phase I and II clinical
trials.3 However, their clinical efficacy is strongly impaired by
compensatory feedback mechanisms that lead to upregulation
and activation of multiple receptor tyrosine kinase and, finally, to
drug resistance.4,5
HER3 is a critical signaling node in the ErbB family and its
activation contributes to cellular adaptation to PI3K inhibitors in
HER2-overexpressing tumors.5–7 In HER2-driven cancers, HER3 is
an important heterodimer partner that binds the PI3K regulatory
subunits and activates the PI3K/AKT survival pathway,8–10
suggesting that the co-inhibition of HER3 and PI3K pathways
may exert a greater antitumor efficacy.7
Actin cytoskeleton and its organization are strongly deregulated
in cancer and affect many signaling pathways related to relevant
cell functions, such as apoptosis, adhesion and migration.11
Human MENA (hMENA) belongs to the ENA/VASP protein family
with key roles in cellular processes governed by the actin
dynamics.12,13 hMENA, overexpressed in 70% of BC with HER2+,
ER/PgR− and high Ki67 phenotype and correlated with an
activated status of MAPK and AKT kinases, has been reported as
an early marker of breast tumorigenesis.14,15 The concomitant
overexpression of HER2 and hMENA identifies a subgroup of BC
patients with a worse prognosis.15 The MENA gene encodes the
570-aa hMENA protein and different splicing-derived isoforms
have been reported in human16,17 and mouse.12,18,19 Two
isoforms, epithelial specific hMENA11a and mesenchymal specific
hMENAΔv6, with opposing regulatory functions in tumor cell
invasion are differently expressed in primary BC.20 hMENA and
hMENA11a are upregulated by epidermal growth factor (EGF) and
Neuregulin (NRG-1) growth factor that specifically phosphorylate
hMENA11a, whereas Trastuzumab treatment downregulates
hMENA expression and inhibits hMENA11a phosphorylation.15,16
Depletion of all hMENA isoforms reduces HER3 phosphorylation,
inhibits EGF- and NRG-1-mediated phosphorylation of EGF-
Receptor (EGFR) and HER2, and impairs growth factor-mediated
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cell proliferation.15 Given the role of hMENA11a isoform in tumor
cell proliferation and its cross talk with ErbB receptors,15 we set up
a phospho-proteomic analysis to investigate the role of hMENA11a
in different oncogenic signaling pathways related to proliferation
and survival. Here, we show that the hMENA11a overexpression
correlates with HER3 and P-HER3 in HER2-overexpressing BC
tissues. In HER2+ BC cells, our results indicate that hMENA11a is an
anti-apoptotic regulator involved in the HER3-mediated mechan-
isms of resistance to PI3K inhibition.
RESULTS
RPPA analysis reveals that hMENA11a silencing inhibits HER3/AKT
activation in MDA-MB-361 cells
To examine the role of hMENA11a overexpression on oncogenic
signaling pathways related to cell proliferation and survival, we set
up a reverse phase protein array (RPPA) analysis of 85 proteins and
phospho-proteins (Supplementary Figure 1). We compared the
phospho-proteomic profiles of the luminal BC cell line MDA-
MB-361, which overexpresses HER2 and hMENA/hMENA11a, before
and after hMENA11a-specific silencing (MDA-MB-361 si-CNTR vs
MDA-MB-361 si-hMENA11a). The hMENA11a silencing specifically
downregulates the hMENA11a protein level, but does not modify
the hMENA protein level (Supplementary Figure 2). The heatmap
in Figure 1a shows the hierarchical clustering of 59 significant
endpoints; MDA-MB-361 control cells displayed a sustained
activation of several oncogenic pathways, for example, HER2
and EGFR, and a moderate activation of HER3. hMENA11a silencing
significantly downregulated the phosphorylation of EGFR (Y1068
and Y1148), HER2 (Y1248) and HER3 (Y1289); among other
receptor tyrosine kinases, it reduced the activation levels of cKit,
Met and ALK, indicating that hMENA11a plays a critical role in
sustaining the activation of different oncogenic signals. A number
of survival proteins, such as survivin, were downregulated by
hMENA11a silencing, while proteins such as H2AX and the cleaved
forms of PARP and CASP9, all features of the apoptotic process,
were upregulated. Overall, these RPPA data evidence a crucial role
of hMENA11a in sustaining signaling pathways related to cell
proliferation and survival.
NRG-1 promotes hMENA11a overexpression and phosphorylation,15
thus we performed RPPA analysis on MDA-MB-361 cells (si-CNTR
and si-hMENA11a) after NRG-1 treatment. A strong increase of
Figure 1. RPPA analysis reveals that hMENA11a sustains HER3/AKT axis in MDA-MB-361 cells. (a) Two-way unsupervised hierarchical clustering
analysis (average method) for 59 proteins with significant differences (Po0.05, Dunnett’s test) in MDA-MB-361 cells transfected with
nontargeting si-RNA (si-CNTR) and hMENA11a-specific si-RNAs (si-hMENA11a), serum starved overnight and untreated or treated with 10 nM
NRG-1 for 24 h. Red color represents the higher relative levels of activity/expression, black the intermediate levels and green the lower relative
levels of activity/expression. Experiment was performed in biological triplicates indicated as 1, 2, 3 in the heatmap. (b) Validation of RPPA
results by WB analysis for P-HER3 and P-AKT. Densitometric quantitation of protein bands was determined by NIH ImageJ software. P-HER3
signals were normalized in comparison with total HER3 and fold increase or decrease is indicated with respect to si-CNTR-untreated cells.
P-AKT signals were normalized in comparison with total AKT and fold decrease is indicated with respect to si-CNTR NRG-1-treated sample.
HSP70 was used as the loading control.
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HER3 activation, paralleled by a slight reduction of HER2 and EGFR
phosphorylation, occurred in MDA-MB-361 cells treated with
NRG-1 (Figure 1a), suggesting that NRG-1 preferentially elicits
HER3 and downstream targets AKT (S473) and p70S6K (T389)
phosphorylation. Of note, NRG-1 treatment also increased insulin
receptor substrate 1 (IRS1) phosphorylation, as previously reported
for ER+ BC cell lines.21 Differently, as evidenced in the heatmap
(Figure 1a), hMENA11a silencing impairs NRG-1-mediated activa-
tion of the HER3/AKT axis. These results were validated by western
blot (WB) (Figure 1b).
When we assessed whether HER3 could reciprocally affect
hMENA11a expression, we evidenced that HER3 silencing does
not affect hMENA11a expression either in MDA-MB-361 or in
MCF7 cells transfected with HER2 (MCF7-HER2) (Supplementary
Figure 2).
Overall, phospho-proteomic analysis and its WB validation
revealed that hMENA11a sustains HER3 activation and its down-
stream, pro-survival AKT pathway, suggesting a role for this
hMENA isoform in survival and proliferation signals.
hMENA11a expression correlates with HER3 expression and
phosphorylation in HER2-overexpressing BC patients
To investigate whether the strong correlation between hMENA11a
and HER3 activation evidenced by RPPA analysis occurs also
in vivo, hMENA11a isoform expression was evaluated by immuno-
histochemistry in parallel with HER3 and Y1289 P-HER3 antibodies
in a series of 49 HER2-positive invasive ductal breast carcinomas
consecutively selected from the surgical pathology files of the
Regina Elena National Cancer Institute (Rome, Italy) with the
approval of the Ethical Committee and written informed consent
obtained from all patients. Clinicopathologic information of
patients is listed in Supplementary Table 4.
Ninety-five percent of cases showing a 2+, 3+ P-HER3 score (for
representative scores, see Supplementary Figure 3) were con-
comitantly positive for hMENA11a (P⩽ 0.0001), evidencing a strong
correlation between hMENA11a and HER3 activation (Table 1).
Although to a lesser extent, HER3 expression also correlates with
hMENA11a expression (P= 0.008) (data not shown). A phosphory-
lated status of HER3 was evidenced in 61% of the 31 HER3-positive
cases (Supplementary Table 5). Representative cases stained with
hMENA11a, HER3 and P-HER3 antibodies are reported in Figure 2.
Of note, cases which evidence a strong HER3 phosphorylation
(score 2+, 3+) show an intense membranous staining of
hMENA11a, whereas, when P-HER3 is negative or low scored
(score 0, 1+), staining of hMENA11a is diffuse and cytoplasmic,
leading us to hypothesize that the hMENA11a relocalization is
suggestive of a still to be elucidated function, related to HER3
activation. These in vivo results indicate that hMENA11a over-
expression is associated with HER3 activation in BC tissues and
may represent a useful marker of HER3 activity.
hMENA11a silencing impairs HER3 activation and FOXO3a-
mediated HER3 upregulation induced by PI3K inhibitors
Given the critical role of HER3 in drug resistance and in treatment
failure of PI3K inhibitors,7 we investigated whether hMENA11a is
involved in the mechanisms of HER3-mediated resistance to PI3K
inhibitors in HER2-overexpressing BC cells. To test this hypothesis,
MCF7-HER2 cells harboring constitutive activation of PI3K (E545K
PIK3CA) were specifically silenced for hMENA11a and treated with
the dual PI3K/mTOR inhibitor BEZ235.22 WB analyses showed that
HER3 and AKT were constitutively active in MCF7-HER2 control
cells (si-CNTR) (Figure 3a). hMENA11a silencing reduced P-HER3
and P-AKT levels without affecting their expression. As expected,
treatment with BEZ235 (24 h) completely inhibited P-AKT and
P-S6. Consistent with previous reports,4,7 the drug upregulated
HER3 expression and activation. However, when the cells were
silenced for hMENA11a, the effect of BEZ235 treatment on HER3
was impaired (Figure 3a). Similar results were obtained upon
BEZ235 treatment of MDA-MB-361 cells (Supplementary Figure 4).
Figure 2. hMENA11a expression correlates with P-HER3 in HER2-positive BC. hMENA11a, HER3 and P-HER3 staining of two representative cases
by immunohistochemistry is reported: panels a–c display a strong immunoreactivity against (a) hMENA11a, (b) HER3 and (c) P-HER3; panels d–f
show (d) a low hMENA11a expression, (e) a strong HER3 staining and (f) a low P-HER3 staining. Scale bar 30 μm. Inset magnification × 40.
Table 1. hMENA11a strongly correlates with HER3 phosphorylation
status (P-HER3) in HER2-positive breast carcinomas
hMENA11a
P-HER3 Positive 2+/3+ Negative 0/1+ Total cases P value
Positive 2+/3+ 18 (95%) 1 (5%) 19
Negative 0/1+ 11 (37%) 19 (63%) 30
Total cases 29 (59%) 20 (41%) 49 o0.0001
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By qRT–PCR, we quantified the levels of HER3 mRNA in MCF7-
HER2 cells upon PI3K inhibition by either BEZ235 (Figure 3b)
or LY294002 (ref 23) (Supplementary Figure 4b). The HER3 mRNA
upregulation mediated by PI3K inhibition was impaired by
hMENA11a silencing, whereas no effect was evident in untreated
cells (Figure 3b), in agreement with data at protein level.
PI3K inhibitors increase HER3 transcription through deregula-
tion of the transcription factor FOXO3a.5,24 FOXO3a nuclear
translocation is impaired by AKT-mediated phosphorylation,
whereas downregulation of P-AKT due to PI3K inhibition results
in FOXO3a nuclear accumulation and increase of HER3
transcription.5,24
Thus, we asked whether hMENA11a overexpression may affect
FOXO3a subcellular localization by analyzing MCF7-HER2 control
cells (si-CNTR) and hMENA11a-silenced cells (si-hMENA11a)
untreated or BEZ235-treated. In the majority of the untreated
cells, FOXO3a was simultaneously found in both nucleus and
cytoplasm, and hMENA11a silencing did not modify FOXO3a
localization (Figure 3c). As expected, BEZ235 treatment resulted in
FOXO3a nuclear accumulation in 85% of si-CNTR cells followed by
HER3 mRNA upregulation (Figures 3d and b). Differently,
hMENA11a silencing impaired BEZ235-mediated FOXO3a nuclear
accumulation (Figure 3c). Only 29% of cells showed a FOXO3a
nuclear localization (Figure 3d). Similar results were obtained in
MDA-MB-361 cells by using three different PI3K inhibitors
(Supplementary Figure 4c).
These immunofluorescence results were confirmed by bio-
chemical experiments on fractionated cell lysates evidencing that
nuclear accumulation of FOXO3a upon BEZ235 treatment was
impaired in silenced hMENA11a cells, at 24 h and even at short
incubation (6 h) (Figure 3e). Taken together, these data
suggest that hMENA11a sustains the PI3K inhibition-mediated
HER3 upregulation, at least in part, by allowing FOXO3a nuclear
accumulation.
PI3K inhibitor treatment affects hMENA11a phosphorylation and
localization
To investigate the functional role of hMENA11a in the compensa-
tory pathways involved in the resistance to PI3K inhibitors, we
analyzed whether BEZ235 treatment affects hMENA11a expression
levels and we found that the treatment does not modify
hMENA11a expression levels (Figure 4a).
However, immunofluorescence analysis evidenced a different
subcellular localization of hMENA11a in the untreated (CNTR) vs
PI3K inhibitor-treated cells. A diffuse cytoplasmic pattern of
Figure 3. hMENA11a silencing impairs HER3 activation and FOXO3a-mediated HER3 upregulation induced by PI3K inhibitors. (a) Lysates from
MCF7-HER2 cells transfected with nontargeting si-RNA (si-CNTR) or hMENA11a-specific si-RNAs (si-hMENA11a) and treated with 0.5 μM BEZ235 in
10% fetal calf serum containing medium for 24 h, were immunoblotted against the indicated antibodies. HSP70 was used as the loading
control. Densitometric quantitation of protein bands was determined by NIH ImageJ software. P-HER3, P-AKT and P-S6 signals were
normalized in comparison with total HER3, AKT and S6 signals, respectively; HER3 signals were normalized in comparison with HSP70. Fold
increase or decrease were calculated with respect to si-CNTR-untreated cells. (b) Real-time qPCR with HER3-specific primers of RNA from
MCF7-HER2 cells transfected with si-CNTR and hMENA11a-specific siRNAs untreated and treated with 0.5 μM BEZ235 for 24 h. All experiments
were repeated three times, each time in triplicate. Each bar represents the mean± s.d. of three independent experiments. *P⩽ 0.05 (c)
Subcellular distribution of FOXO3a determined by immunofluorescence analysis of MCF7-HER2 cells transfected with si-CNTR and hMENA11a-
specific si-RNAs and treated with 0.5 μM BEZ235 for 24 h. Cells were stained with FOXO3a antibody (green) and nuclei were visualized by 4’6-
diamidino-2-phenylindole (blue). Magnification × 63. Scale bar 30 μm. (d) Quantification of the FOXO3a subcellular distribution patterns,
nuclear (N), cytoplasmic (C) or nuclear and cytoplasmic (N/C), is shown as the mean± s.d. of three experiments. **P⩽ 0.01. (e) WB analysis of
cytoplasmic and nuclear fractions of MCF7-HER2 si-CNTR and si-hMENA11a cells, untreated or treated with 0.5 μM BEZ235 for 6 and 24 h and
subjected to nuclear and cytoplasmic fractionation. Lysates were immunoblotted against the indicated antibodies. Histone H3 and tubulin
were used as loading controls of nuclear and cytoplasmic fractions, respectively.
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hMENA11a was revealed in the CNTR cells, whereas PI3K inhibitors
determined hMENA11a translocation to the membrane, where it
appears to be organized in structures reminiscent of focal
adhesions (Figure 4b).
hMENA11a is phosphorylated by EGF and NRG-1 mitogenic
signals, whereas Trastuzumab significantly downregulates
hMENA11a phosphorylation, suggesting a cross talk between
hMENA11a and EGFR family signaling.15 Thus, we speculated that
different hMENA11a localization might be related to its phosphor-
ylation status. A two-dimensional electrophoresis conducted on
MDA-MB-361 untreated (CNTR) or treated with the PI3K inhibitor
(XL147)25 showed that the inhibitor determined a shift of
hMENA11a spots toward an acidic pH, a pattern reminiscent of
that previously reported for hMENA11a phosphorylation induced
by EGF or NRG-1 stimulation (Figure 4c).
hMENA11a sustains cancer cell proliferation, survival and resistance
to HER3-mediated PI3K inhibition
Results that hMENA11a overexpression might affect AKT-related
pro-survival signaling pathways prompted us to verify the role of
hMENA11a overexpression at the functional level. We stably
transfected hMENA11a in DAL (thereafter called DAL11a), a breast
cancer cell line with undetectable expression of any of the hMENA
isoforms.26 In DAL11a, the P-HER3 levels were increased, confirm-
ing a link between hMENA11a and HER3 activation in BC cells
(Figure 5a). Of note, the hypothesis that only the epithelial
hMENA11a isoform is linked to HER3 signaling was confirmed by
transfecting DAL cells with the mesenchymal-related hMENAΔv6
isoform20 that did not affect HER3 activation levels (Figure 5b). To
evaluate whether hMENA11a overexpression affects cell prolifera-
tion and survival in response to BEZ235 treatment, we evaluated
dose–response curves in DAL and DAL11a cells. hMENA11a
overexpression determined a shift in BEZ235 IC50 from 67 nM in
DAL compared with 111 nM in DAL11a after 72 h of treatment,
indicating that hMENA11a may be crucial in the resistance of BC
cells to BEZ235 treatment (Figure 5c).
We further evaluated cell cycle distribution by flow cytometry.
hMENA11a silencing impacted on cell proliferation of both MDA-
MB-361 and MCF7-HER2, decreasing the percentage of cells in the
S phase and increasing those in the G1 phase of the cell cycle
(Figure 6a). In agreement with previous observations,27 BEZ235
treatment resulted in an accumulation of cells in the G1 phase
compared with the untreated controls (Figure 6a). Of relevance,
the combination of hMENA11a silencing and BEZ235 treatment
further decreased the percentage of cells in the S phase
(Figure 6a) and induced the accumulation of a sub-G1 peak
(Figure 6b, upper panel), suggestive of cell death. These data were
confirmed by 3H-thymidine incorporation assay (Supplementary
Figure 5).
To evaluate whether the accumulation of cells in the sub-G1
peaks was due to the induction of apoptosis, we assessed the
PARP cleavage, and as shown in Figure 6b lower panel, hMENA11a
has a role in apoptosis as evidenced by the full length and cleaved
pattern of PARP.
Tumors bearing high levels of the Bcl-2 family member BIM are
more susceptible to PI3K inhibitor-mediated apoptosis and BIM
has been proposed as a biomarker of apoptosis sensitivity.28 In
agreement with published results,29 BEZ235 treatment did not
increase BIM in either of the cell lines evaluated. Interestingly, at
least in MDA-MB-361 cells, hMENA11a silencing determined an
increase in BIM levels (Figure 6b), indicating that hMENA11a exerts
an anti-apoptotic role and affects BIM expression.
hMENA11a sustains cancer cell resistance to PI3K inhibition in
three-dimensional (3D) cultured BC cells
It is becoming increasingly evident that 3D cultures better reflect
drug sensitivity in vivo.30,31 Thus, we cultured MCF7-HER2 control
Figure 4. hMENA11a is phosphorylated and relocalized by PI3K
inhibitor treatment. (a) Lysates from MDA-MB-361 cells treated with
0.5 μM BEZ235 for 4, 8 and 24 h, were immunoblotted against
hMENA11a and P-AKT antibodies. Actin antibody was used as the
loading control. (b) Immunofluorescence analysis of MCF7-HER2 and
MDA-MB-361 cells untreated or treated with 0.5 μM BEZ235 (24 h)
and 20 μM XL147 (16 h). Cells were stained with hMENA11a-specific
antibody (green), nuclei with 4’6-diamidino-2-phenylindole (blue).
Magnification × 63. Scale bar 20 μm. (c) 2D-electrophoresis on a pH
4–7 nonlinear range and 10% acrylamide SDS–PAGE of protein
extracts from MDA-MB-361 cells untreated (CNTR) or treated with
20 μM XL147(XL147). Proteins were electrontransferred to nitrocellu-
lose and then incubated with hMENA11a antibody; the shift toward
acidic pH of the hMENA11a-specific spots is indicated by a dashed
line. The arrow indicates hMENA11a-positive spots in MDA-MB-361
CNTR that disappear after XL147 treatment.
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and si-hMENA11a in a laminin-rich extracellular matrix and treated
cells with BEZ235 for 48 h. Si-CNTR cells showed grape-like
structures consistent with morphology previously described for
HER2-overexpressing BC cells,32 while si-hMENA11a cells formed
smaller colonies with a proportional increase in the number of 4’6-
diamidino-2-phenylindole-stained cells (death cells) (Figure 7a).
Morphological analysis at phase contrast microscopy and calcein
staining (live cells) revealed that BEZ235 treatment leads to small
colonies and dramatically reduces mass structures with the
appearance of a major number of single cells in si-hMENA11a
cells (Figure 7a). Immunohistochemical staining of 3D-cultured
cells with Ki67 Ab confirmed that silencing of hMENA11a decreases
Ki67 staining of cells (90 ± 3,3 vs 65%±5), and BEZ235 treatment
of hMENA11a silenced cells further reduces Ki67 staining (65 ± 5 vs
38%±7,2) (Figure 7b).
This 3D analysis confirms the above-reported results with two-
dimensional (2D) cultures and supports the data showing that
hMENA11a silencing reduces cell proliferation and sensitizes cells
to PI3K inhibition.
DISCUSSION
The actin cytoskeleton architecture impacts many cellular
processes and signaling pathways associated with cancer.11
hMENA, an actin regulatory protein, undergoes splicing, and our
group has described two alternatively expressed isoforms,
hMENA11a and hMENAΔv6, with opposite functions in cancer cell
invasion.20 hMENA11a is phosphorylated downstream of HER2 and
EGFR after treatment with NRG-1 and EGF. hMENA11a cooperates
with mitogenic signaling of the ErbB family receptors, and when
hMENA and HER2 are both overexpressed, patients have a worse
prognosis.15 The role of hMENA11a in oncogenic signaling path-
ways has been poorly investigated and the kinase involved in
hMENA11a phosphorylation has not yet been identified. Herein, we
present data suggesting that the overexpression of the epithelial-
associated hMENA11a isoform is correlated with HER3 overexpres-
sion and phosphorylation in HER2-positive tumors, is crucial for
sustaining pro-survival pathways and participates in HER3 activa-
tion, influencing resistance mechanisms to PI3K/mTOR targeted
therapies.
The success in obtaining specific hMENA11a isoform silencing
allowed us to demonstrate that this isoform sustains different
receptor tyrosine kinase signaling pathways. In particular, as
evidenced by RPPA, in HER2-overexpressing BC cells, hMENA11a
sustains the activation of ErbB family receptors, as evidenced by
the downregulation of P-EGFR, P-HER2 and P-HER3 after specific
silencing of this isoform. Even though the mechanisms involved
still need to be elucidated, the results of RPPA suggest that
hMENA11a is critical in sustaining the activation of relevant
pathways involved in cell proliferation and apoptosis, as
Figure 5. hMENA11a transfection in DAL cells increases HER3 activation and resistance to BEZ235 treatment. (a) WB analysis of DAL cells
transfected with empty vector (CNTR) or hMENA11a (DAL11a) with the indicated antibodies. (b) WB analysis of lysates from DAL transfected
with control vector (CNTR) or hMENAΔv6 (DAL-Δv6), with hMENAΔv6 and P-HER3 antibodies. HSP70 was used as the loading control. (c) DAL
and DAL11a cells were incubated with increasing concentrations of BEZ235 for a period of 72 h, fixed and stained with crystal violet. The effect
on viability was reported as a percentage of the number of cells relative to control, defined as 100% survival. Each bar represents the mean± s.
d. of three different experiments.
Figure 6. hMENA11a silencing reduces cell proliferation, induces cell
apoptosis and sensitizes to PI3K inhibition. MDA-MB-361 and MCF7-
HER2 were transfected with nontargeting si-RNA and hMENA11a-
specific si-RNAs and treated with 0.5 μM BEZ235 for 24 h. (a) Cells
were subjected to cell cycle analysis by 5-bromo-2'-deoxyuridine
incorporation assay, the percentage of cells in each phase of cell
cycle is reported. (b) Upper panel: the percentage of cells in sub-G1
phase is reported. Each bar represents the mean± s.d. of three
different experiments. (b) Lower panel: immunoblotting against
hMENA11a, BIM and PARP antibodies is reported. HSP70 antibody
was used as loading control. Asterisk: PARP uncleaved form; arrow:
cleaved form.
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evidenced by the upregulation of critical molecules, such as H2AX
and PARP, when hMENA11a is silenced.
On the basis of our previous data showing that NRG-1
phosphorylates hMENA11a (ref 15) and given the RPPA results,
we performed phospho-proteomic analysis on cells silenced for
hMENA11a and treated with NRG-1. hMENA11a silencing counter-
acts the NRG-1-mediated activation of different key molecules,
including IRS1, reported to be recruited to HER3 following NRG-1
treatment.21 Of note, the phosphorylation of IRS1 provides
docking sites for the recruitment of key signaling pathways.21,33
Interestingly, we found that NRG-1 was unable to activate HER3
signaling in cells lacking hMENA11a, suggesting a critical role of
hMENA11a in HER3/AKT axis activation. This is relevant when
considering the highlighted role of HER3 signaling in HER2-
amplified BC cells.
Expression and signaling functions of HER3 are highly regulated
through a multitude of mechanisms at the transcriptional,
translational and posttranslational levels.34
Our data, showing that hMENA11a silencing decreases HER3
phosphorylation levels without influencing the RNA and protein
levels, support the hypothesis that hMENA11a may participate in a
posttranslational mechanism accounting for HER3 signaling
activation without inducing the expression. At the moment, it is
difficult to speculate on these findings. However, we can
hypothesize that hMENA11a may participate in the highly dynamic
nature of this HER family member, by affecting its localization and
trafficking. Recently Vehlow et al.35 reported that MENA coop-
erates with Lamellipodin and Endophilin to regulate F-actin-
dependent EGFR endocytosis.
Of clinical relevance, our immunohistochemical results clearly
support experimental data and for the first time, highlight the
correlation among hMENA11a, HER3 activation and expression in
HER2-overexpressing breast tumors. Although further studies are
needed, we hypothesize that hMENA11a and its phosphorylation,
affected by different growth factors, are relevant in the activation
of the HER2/HER3 oncogenic unit.
Multiple studies have implicated the functions of HER3 as a
major cause of treatment failure to targeted therapies and HER3
upregulation and activity have been proposed as a major
compensatory feedback mechanism occurring after PI3K inhibi-
tion in HER2-overexpressing cell lines.5,6,36
Thus, we compared the effects of different PI3K inhibitors in
HER2-overexpressing cell lines with respect to hMENA11a silenced
cells. Notably, results at the RNA and protein levels highlight the
role of hMENA11a in sustaining HER3 expression induced by PI3K
inhibition. Indeed, silencing of hMENA11a was able to counteract
the known compensatory effect of HER3 expression and activation
exerted by the dual mTOR/PI3K inhibitor BEZ235. From a
mechanistic point of view, downstream to PI3K inhibition, AKT
when inhibited recruits the transcription factor FOXO3a to the
HER3 promoter enabling HER3 expression.5,24 Of note, we have
found that FOXO3a nuclear accumulation determined by PI3K
inhibition was impaired by hMENA11a silencing, with a crucial
effect on HER3 transcription. The FOXO3a subcellular localization
depends on the dynamic interactions with the Protein Phospha-
tase 2A (PP2A) and the scaffold proteins 14-3-3.37 After inhibition
of PI3K, the FOXO3a phosphorylation is no longer favored and
PP2A and FOXO3a translocate into the nucleus after dissociation
from 14-3-3.37 Of relevance, as evaluated by ELM (Eukaryotic
Linear Motifs) server (http://elm.eu.org/),38 the hMENA11a
sequence has four interacting motifs for 14-3-3, known to
participate at the regulation of cytoskeleton.39 Two out of the
four motifs identified in silico are phospho-motifs present only in
the 11a isoform, being located in the 21 aa sequence of the 11a
peptide. Further studies, validating this predictive binding
between hMENA11a and 14-3-3, will provide evidence supporting
the hypothesis that hMENA11a via 14-3-3 binding may affect
FOXO3a nuclear localization. Hence, the overexpression of this
isoform and above all, its phosphorylation status may affect
relevant molecular complexes involved in the transcription of
HER3. hMENA11a amino-acid residues that are phosphorylated by
growth factors15,16 have not yet been identified. Also, the kinase
Figure 7. hMENA11a silencing reduces cell proliferation in 3D-cultured MCF7-HER2 cells and enhances antiproliferative effect of BEZ235. MCF7-
HER2 cells were transfected with nontargeting si-RNA (si-CNTR) or hMENA11a-specific si-RNAs (si-hMENA11a), grown on laminin-rich
extracellular matrix and untreated or treated with 0.5 μM BEZ235 for 48 h. (a) Cells were stained with calcein (green) and 4’6-diamidino-2-
phenylindole (blue) and imaged by Leica DM IRE2 microscopy. Magnification × 20. Scale bar 50 μm. (b) Matrigel/cells blocks were included in a
Histogel 'sandwich' and embedded in paraffin, sectioned and immunostained with hMENA11a (left) and Ki67 (right) antibodies. Scale bar
30 μm. Representative images of three different experiments are shown.
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involved is yet to be identified. The 2D electrophoresis analysis
clearly showed that PI3K inhibitor treatment, which does not
affect hMENA11a expression, induces phosphorylation of
hMENA11a, which in turn shifts its localization from the cytoplasm
to the membrane. Consistent with these results, it has been
recently reported that several of the phosphoproteins activated by
PI3K pathway inhibitors are related to cytoskeletal reorganization
and are proposed as candidate pharmacodynamic biomarkers for
PI3K/AKT/mTOR drug development.40 Although the mechanisms
have to be further elucidated, our results suggest that hMENA11a
overexpression and phosphorylation affect the HER3 phosphoryla-
tion and expression by mechanisms that are independent of each
other. HER2 is the main kinase responsible for HER3 activation
occurring after PI3K inhibition in HER2-overexpressing BC cells,4
and we have previously reported that Trastuzumab treatment
downregulates hMENA11a expression and phosphorylation,15 thus,
suggesting that hMENA11a overexpression and phosphorylation
may sustain the HER2/HER3 dimer.
Recently, actin-binding proteins have been proposed as sensors
and mediators of apoptosis, and remodeling of the actin
cytoskeleton may enable tumor cells to escape normal apoptotic
signaling.41 No data are available on the role of hMENA or its
isoforms in apoptotic processes, although we have previously
reported that hMENA11a overexpression favors the proliferation
rate of BC cells.16 Our findings are consistent with the hypothesis
that hMENA11a sustains an anti-apoptotic signaling in BC cells. Of
clinical relevance, hMENA11a overexpression increases the resis-
tance of BC cells to BEZ235 treatment, whereas its silencing
sensitizes cells to BEZ235-induced death. Furthermore, the results
that the hMENA11a silencing reduces the expression of the pro-
apoptotic Bcl-2 family member BIM,42 critical mediator of targeted
therapy-induced apoptosis,28 corroborate the hypothesis that
hMENA11a promotes a survival advantage in BC cells.
The 3D models better recapitulate signaling pathways related to
proliferation and survival43 and have been reported as relevant
systems to study cancer cell resistance to PI3K/mTOR inhibition.44
Our monolayer culture results were validated in 3D, enforcing the
role of hMENA11a in mechanisms of resistance to the dual inhibitor
BEZ235.
Although further studies are required, our results hold promise
for multi-fold clinical implications. We can speculate that
hMENA11a expression may be proposed as a marker of HER3
activity, which lacks validated specific markers hampering the
progress of HER3-targeted therapy.45 Moreover, the specific
expression of this hMENA isoform in combination with BIM may
permit the selection of patients less likely to respond or those who
may derive maximal benefit from therapies including PI3K/mTOR
inhibitors. There is hope that the identification of drugs able to
shut down hMENA11a activity may lead to the design of more
effective antiproliferative therapies in BC.
MATERIALS AND METHODS
Cell lines and treatments
The human breast carcinoma cell lines MDA-MB-361 and MCF7 were
obtained from the ATCC; MCF7-HER2 stable transfectants were obtained as
previously described.15 DAL cell line, DAL11a and DALΔv6 transfectants
were obtained as previously reported.20,46 All cell lines were routinely
tested for ER status, morphologically checked by microscope, growth curve
analysis by 3H-Thymidine incorporation assay and Mycoplasma detection
(Roche, Monza, Italy).
NRG-1 (PeproTech, Rocky Hill, NJ, USA) was added to serum-starved cells
at a concentration of 10 ng/ml. BEZ235 (0.5 μM, Selleck Chemicals, Houston,
TX, USA), XL147 (20 μM, Selleck Chemicals) and LY294002 (10 μM, Cell
Signaling Technology, Danvers, MA, USA) were used.
Small-interfering RNA (siRNA) treatment
Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) with 100 nmol/l of ON-TARGETplus Nontargeting Control Pool (GE-
Healthcare, Dharmacon, Lafayette, CO, USA), or HER3 siRNA. Specific
hMENA11a silencing was performed by transfecting cells with a mix of three
siRNAs (30 pmol each) each matching 21 nucleotides within the 11a exon
sequence. The siRNAs sequences used are reported in Supplementary
Table 6.
For NRG-1 stimulation, 24 h after the transfection, cells were serum-
starved for 18 h and then treated with NRG-1; for PI3K inhibitor treatments,
48 h after the transfection, cells were treated with XL147 in 2.5% serum
containing medium or with BEZ235 or LY294002 in complete medium.
Cells were processed 72 h after the transfection.
Reverse phase protein array
Protein lysate preparation and RPPA were performed on biological
triplicate samples, as previously reported.47 Supplementary Table 1 reports
detailed information concerning the antibodies used.
Spot intensity was analyzed by MicroVigene software V5.1 (VigeneTech,
North Billerica, MA, USA), and normalized to total protein and standar-
dized. RPPA data were subjected to unsupervised statistical analysis
(average method) using JMP V10.0.2 (SAS Institute, Cary, NC, USA).
Statistically significant endpoints were evaluated using the multiple
comparison Dunnett's test. P valueso0.05 were considered significant.
The lists of total significant and nonsignificant endpoints were reported in
Supplementary Tables 2 and 3.
WB analysis
WB was performed as reported.15 Nuclear and cytoplasmic fractions were
prepared using NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce,
Rockford, IL, USA). Anti-hMENA11a, pan-hMENA and hMENAΔv6 were used
as already described.14,15,20 Anti-HER3 #12708, P-HER3 (Y1289) #4791,
P-AKT (S473) #4060, AKT #4685, P-S6 (S240/244) #2215, S6 #2217, BIM
#2819, PARP #9542 (Cell Signaling Technology), anti H3 #Ab-1791 (Abcam,
Cambridge, UK), anti-β actin #A4700 (Sigma-Aldrich, Poole, UK), HSP70 #sc-
24 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), anti-FOXO3a #04-
1007 (EMD Millipore Corporation, St Charles, MO, USA) were used.
Immunohistochemistry
HER2, ER, PgR and Ki67 status and hMENA11a expression were assessed on
tissues from 49 HER2-positive BC patients as previously reported.20 HER3
(#NCL-cerbB-3, Novocastra Leica, Menarini, Florence, Italy) and P-HER3 (Cell
Signaling Technology) antibodies were used. For HER3, P-HER3 and
hMENA11a, an immunohistochemistry (IHC) score of 2/3 on the membrane
or cytoplasm was defined as positive. For statistical analysis, negative
(score 0/1) and positive (score 2/3) groups were created. Evaluation of the
IHC results was performed independently by two investigators (MM, ADB)
blinded to patient data.
RNA extraction and real-time PCR
Total RNA extraction and cDNA synthesis were performed as reported.20
HER3 primers used were: 5′-GGGGAGTCTTGCCAGGAG-3′ and 5′-
CATTGGGTGTAGAGAGACTGGAC-3′. GAPDH primers were used as an
internal control. qRT–PCR was performed with 10 ng cDNA in ABI Prism
7900 Real-time PCR system using SYBR Green PCR Master Mix (Applied
Biosystems, Princeton, NJ, USA). Gene expression was calculated using the
equation 2−ΔΔCt.48
Immunoflorescence
Cells transfected with siRNAs and/or treated with PI3K inhibitors were fixed and
permeabilized as previously described.20 Cells were stained with anti-hMENA11a
and/or anti-FOXO3a antibodies. Nuclei were stained with 4’6-diamidino-2-
phenylindole (Invitrogen). Immunofluorescence was analyzed by Leica DM IRE2
microscopy with Leica FW 4000 software (Leica, Solms, Germany).
2D electrophoresis
2D electrophoresis was performed as previously described.15
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Crystal violet assay
Cells (5 × 104) seeded in triplicates in 24-well plates were treated with
increasing doses of BEZ235 for 72 h. Cells were fixed with 4%
formaldehyde and stained with 0.1% crystal violet (Sigma). The dye was
subsequently extracted with 10% acetic acid, its absorbance was
determined (570 nm) and the percentages of surviving cells relative to
control, defined as 100% survival, were reported. IC50 values were
calculated by Calcusyn software.
3H-Thymidine incorporation assay
3H-Thymidine incorporation assay was performed as reported.15
Cell cycle analysis
Cell cycle was analyzed with FITC BrdU-Flow KIT (BD Pharmingen, San Jose,
CA, USA) according to the manufacturer’s instructions. Cells were acquired
on FACSCanto II Flow Cytometer (BD Biosciences, San Jose, CA, USA).
Live/dead assay and IHC in 3D cell cultures
Cells (1 × 105) were seeded on top of a growth factor reduced
reconstituted basement membrane Matrigel (BD Pharmingen) containing
5% (vol/vol) laminin-rich extracellular matrix and plated in six-well plates
for live/dead assay or into an eight-well plastic-chambered glass
microscope slide (Thermo Scientific Nunc Lab-Tek II Chamber Slide System,
Thermo Fisher Scientific, Waltham, MA, USA) for IHC. The day after, 0.5 μM
BEZ235 was added for 48 h. For live/dead assay, cells were incubated for
30min at 37 °C with 100 μM calcein AM (Invitrogen) and 0.1 μg/ml 4’6-
diamidino-2-phenylindole to stain viable and nonviable cells, respectively.
Intensity of fluorescence was assessed as reported above. For IHC, 3D cell
cultures were processed as previously reported49 and immunostained with
hMENA11a and Ki67 (#M724001, DAKO, Milan, Italy) antibodies.
Statistical analysis
All experiments were repeated a minimum of three times. Data are
expressed as the mean± s.d. Statistical significance was determined by
Student’s t test (two-tailed) comparison between two groups of datasets,
with similar variance. Asterisks indicate significant differences of experi-
mental groups compared with the corresponding control condition
(Po0.05). To assess the relationship between categorical variables, Fisher’s
exact text was used when appropriate. A P value of o0.05 was considered
statistically significant. To calculate the sample size for immunohisto-
chemical study, we based on the percentage of HER2/HER3 positivity with
respect to hMENA11a expression in BC cell lines.20,50 The proportion of
HER2/HER3 positivity was equal to 80% in hMENA11a-positive BC and 40%
in hMENA11a-negative BC. Applying a two-sided Z-test with pooled
variance, assuming a statistical power equal to 80% and a significance
level equal to 0.05, we needed to recruit a minimum of 46 patients.
Statistical analyses were carried out using SPSS software (SPSS version
21, SPSS Inc., Chicago, IL, USA). The data presented in some figures are
from a representative experiment, which was qualitatively similar in the
replicate experiments.
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